New Zealand markets open in 8 hours 18 minutes

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7500+0.0100 (+0.57%)
As of 09:37AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.7400
Open1.7900
Bid1.6800 x 100
Ask1.9400 x 100
Day's range1.7400 - 1.7900
52-week range0.9700 - 3.2100
Volume944
Avg. volume85,280
Market cap9.982M
Beta (5Y monthly)0.54
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

    AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Melissa Moore, Ph.D., Vice President, Clinical Research and Development, will give a presentation at 11:30 a.m. EDT at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on

  • GlobeNewswire

    Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

    Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceu

  • GlobeNewswire

    Plus Therapeutics Announces New Employment Inducement Grants

    AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on May 8, 2024, it granted option awards to Charles Huang, the Company’s new Director of Capital Markets and Investor Relations. The Company agreed to grant these equity awards to Mr. Huang to induce him to commence emp